Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label, Single Arm Study of MK-7119 in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic HER2+ Breast Carcinoma

NCT04721977 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04721977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04721977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label, Single Arm Study of MK-7119 in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic HER2+ Breast Carcinoma
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 8, 2021
Completion date
December 31, 2026
Enrollment
66 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer